florbetapir (Amyvid) Report issue

Small molecule Imaging Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Florbetapir (18F) (trade name AMYViD; also known as florbetapir-fluorine-18 or 18F-AV-45) is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18, recently FDA approved as a diagnostic tool for Alzheimer's disease. Florbetapir, like Pittsburgh compound B (PiB), binds to beta-amyloid, however fluorine-18 has a half-life of 110 minutes, in contrast to PiB's radioactive half life of 20 minutes. Wong et al. found that the longer life allowed the tracer to accumulate significantly more in the brains of people with AD, particularly in the regions known to be associated with beta-amyloid deposits. A negative Amyvid scan indicates sparse to no neuritic plaques, and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvidis an adjunct to other diagnostic evaluations   NCATS

Chemistry

  • SMILES: CNc1ccc(\C=C\c2ccc(OCCOCCOCCF)nc2)cc1
  • InChIKey: YNDIAUKFXKEXSV-NSCUHMNNSA-N
  • Mol. Mass: 360.43
  • ALogP: 3.68
  • ChEMBL Molecules:
    florbetapir  
    florbetapir f 18  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Imaging: 18-fluorine
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

18f av45 | 18f av-45 | 18f-av-45 | [18f]florbetapir | 18f florbetapir | 2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-5-(4-methylaminostyryl)pyridine | 4-(2-(6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-n-methylbenzamide | 4-{(e)-2-[6-(2-{2-[2-(18f)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-n-methylaniline | amyvid | av-45 | florbetapir | florbetapir (18f) | florbetapir f18 | florbetapir f 18 | florbetapir f-18 | florbetapir f 18 injection | florbetapir-fluorine-18 | mni-798 | mni-952

Organizations (41)

Research & Development (41)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (1)


 

Alzheimer Disease (approved 2012)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Alzheimer Disease (Phase 4)

Amyloidosis (Phase 4)

Brain Injuries, Traumatic (Phase 2)

Chronic Traumatic Encephalopathy (Phase 2)

Cognition Disorders (Phase 3)

Cognitive Dysfunction (Phase 2/Phase 3)

Corticobasal Degeneration (Phase 1)

Dementia (Phase 3)

Depressive Disorder, Major (Phase 2)

Frontotemporal Dementia (Phase 2)

Glioblastoma (Phase 2)

Healthy Volunteers (Early Phase 1)

Lewy Body Disease (Phase 1/Phase 2)

Memory Disorders (Phase 1)

Multiple Sclerosis (Early Phase 1)

Neurodegenerative Diseases (Phase 2)

Parkinson Disease (Phase 2)

Postoperative Cognitive Complications (Phase 4)

Stroke (Phase 2)

Supranuclear Palsy, Progressive (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 72
  • # of Trial Organizations: 41

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue